Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Gains from Investment Securities: 2011-2025

Historic Gains from Investment Securities for Catalyst Pharmaceuticals (CPRX) over the last 11 years, with Jun 2025 value amounting to $219,000.

  • Catalyst Pharmaceuticals' Gains from Investment Securities was N/A to $219,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $75.2 million, marking a year-over-year change of. This contributed to the annual value of $13.1 million for FY2024, which is 7.76% down from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Gains from Investment Securities of $219,000 as of Q2 2025, which was down 98.26% from $12.6 million recorded in Q1 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Gains from Investment Securities ranged from a high of $53.0 million in Q4 2024 and a low of -$76,000 during Q1 2021.
  • Moreover, its 3-year median value for Gains from Investment Securities was $477,000 (2023), whereas its average is $12.6 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Gains from Investment Securities slumped by 202.70% in 2021 and then spiked by 22,781.62% in 2022.
  • Catalyst Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $136,000 in 2021, then soared by 22,781.62% to $31.1 million in 2022, then tumbled by 30.15% to $21.7 million in 2023, then surged by 143.95% to $53.0 million in 2024, then surged by 6,065.50% to $219,000 in 2025.
  • Its Gains from Investment Securities stands at $219,000 for Q2 2025, versus $12.6 million for Q1 2025 and $53.0 million for Q4 2024.